Viloxazine ER: A Nonstimulant in ADHD Treatment

Viloxazine extended-release (ER) is a nonstimulant medication approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children 6 years and older, adolescents, and adults. Originally developed decades ago as an antidepressant in Europe, viloxazine was re-engineered and reintroduced with a new formulation for ADHD.¹ Unlike traditional stimulant medications, viloxazine ER offers a different mechanism of action and a lower risk of abuse, making it an attractive alternative for certain patient populations.^2,3

The therapeutic action of viloxazine ER primarily involves modulation of norepinephrine and serotonin levels in the brain.^2,3 It acts as a norepinephrine reuptake inhibitor (NRI), increasing the amount of norepinephrine available in the synaptic cleft, which plays a key role in attention and behavior regulation.^2,3 Additionally, viloxazine has been shown to affect serotonin receptors, particularly 5-HT_2B and 5-HT_2C, suggesting that its benefits in ADHD may stem from a broader neuromodulatory effect than that of NRIs alone.^2,3

What sets viloxazine ER apart is its favorable safety profile and ability to reduce other comorbid conditions, including depression and anxiety.¹ Clinical trials have shown it to be effective in reducing both inattentive and hyperactive-impulsive symptoms with minimal side effects as well as in treating depression and anxiety.^1,2 It also avoids the cardiovascular risks and abuse potential that can accompany stimulant use, offering more peace of mind to caregivers and clinicians managing long-term treatment plans.^1,2 As interest grows in personalized ADHD management, viloxazine ER stands out as a nonstimulant option that broadens the therapeutic landscape. 

References:

1. Findling RL, Candler SA, Nasser AF, et al. Viloxazine in the management of CNS disorders: A historical overview and current status. CNS Drugs. 2021;35(6):643-653. doi:10.1007/s40263-021-00825-w
2. Edinoff AN, Akuly HA, Wagner JH, et al. Viloxazine in the treatment of attention deficit hyperactivity disorder. Front Psychiatry. 2021;12:789982. Published 2021 Dec 17. doi:10.3389/fpsyt.2021.789982
3. Qelbree. Prescribing Information. Supernus Pharmaceuticals; 2023. Accessed March 30, 2025. https://www.supernus.com/sites/default/files/Qelbree-Prescribing-Info.pdf